Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEARL 3: Lurasidone vs placebo and quetiapine XR in acutely psychotic subjects with schizophrenia
2008-003984-38Phase 3Completed
- Sponsor
- Sumitomo Pharma
- Start
- Jul 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of lurasidone in schizophrenia (4 arms), sponsored by Sumitomo Pharma. Primary endpoints: Primary: Change in PANSS total score at Week 6 and Primary (described in text): Change in CGI-S at Week 6. Started Jul 2009; status: completed.
02
Drugs
lurasidone
03
Conditions
schizophrenia
Beyond the preview
Go deeper on 2008-003984-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-003984-38.